Calcium Channel Blockers use not associated with worse HF outcomes

Written By : Jacinthlyn Sylvia |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2023-10-12T11:30:39+05:30 | Updated On 12 Oct 2023 3:09 PM IST

A recent study published in the European Journal of Heart Failure found calcium channel blockers (CCBs) safe and effective in heart failure patients with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF).

The study gathered individual patient data from four large HFpEF/HFmrEF trials and included a substantial cohort of 16,954 patients. Among them, 79% had HFpEF, and 34.6% received CCBs, with dihydropyridines being the most commonly prescribed subtype.

Overall, patients treated with CCBs did not experience higher risks of death or HF-related hospitalization, especially those who took dihydropyridine CCBs. Interestingly, CCB use was even linked to a significantly lower risk of pump failure death. However, it's worth noting that the risk of stroke was slightly elevated in CCB-treated patients.

These findings persisted even after adjusting for other prognostic variables, providing more confidence in the results. Importantly, whether patients received dihydropyridine or non-dihydropyridine CCBs, the outcomes remained largely consistent, suggesting a favorable safety profile for CCBs overall.

While the study acknowledges its observational nature and the absence of randomized treatment, its results carry substantial weight in the field of heart failure management. These findings could provide reassurance to both healthcare providers and patients, potentially expanding treatment options for those with HFmrEF and HFpEF.

This research represents a significant step forward in understanding the role of CCBs in managing heart failure, ultimately, offering hope for improved outcomes and a better quality of life for patients dealing with these conditions.

Source:

Matsumoto, S., Kondo, T., Yang, M., Campbell, R. T., Docherty, K. F., de Boer, R. A., Desai, A. S., Lam, C. S. P., Rouleau, J. L., Vaduganathan, M., Zannad, F., Zile, M. R., Solomon, S. D., Jhund, P. S., & McMurray, J. J. V. (2023). Calcium channel blocker and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. In European Journal of Heart Failure. Wiley. https://doi.org/10.1002/ejhf.3044

Source : European Journal of Heart Failure

Jacinthlyn Sylvia

Neuroscience Masters graduate

Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751